Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Trial of LY3209590 vs Insulin Degludec in Type 1 Diabetes Mellitus
2019-003589-41Phase 2Active
- Sponsor
- Eli Lilly and Company
- Start
- Feb 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of Insulin efsitora alfa in diabetes mellitus type 1 (T1D) (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Change from baseline in hemoglobin A1c (HbA1c). Started Feb 2020; status: active.
02
Drugs
Insulin efsitora alfa
03
Conditions
diabetes mellitus type 1 (T1D)
Beyond the preview
Go deeper on 2019-003589-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003589-41.